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Abstract
Microarray analysis of promoter hypermethylation provides insight into the role and extent
of DNA methylation in the development of colorectal cancer (CRC) and may be co-moni-
tored with the appearance of driver mutations. Colonic biopsy samples were obtained
endoscopically from 10 normal, 23 adenoma (17 low-grade (LGD) and 6 high-grade dys-
plasia (HGD)), and 8 ulcerative colitis (UC) patients (4 active and 4 inactive). CRC sam-
ples were obtained from 24 patients (17 primary, 7 metastatic (MCRC)), 7 of them with
synchronous LGD. Field effects were analyzed in tissues 1 cm (n = 5) and 10 cm (n = 5)
from the margin of CRC. Tissue materials were studied for DNA methylation status using
a 96 gene panel and for KRAS and BRAFmutations. Expression levels were assayed
using whole genomic mRNA arrays. SFRP1 was further examined by immunohistochem-
istry. HT29 cells were treated with 5-aza-2’ deoxycytidine to analyze the reversal possibil-
ity of DNA methylation. More than 85% of tumor samples showed hypermethylation in 10
genes (SFRP1, SST, BNC1,MAL, SLIT2, SFRP2, SLIT3, ALDH1A3, TMEFF2,WIF1),
whereas the frequency of examined mutations were below 25%. These genes distin-
guished precancerous and cancerous lesions from inflamed and healthy tissue. The
mRNA alterations that might be caused by systematic methylation could be partly
reversed by demethylation treatment. Systematic changes in methylation patterns were
observed early in CRC carcinogenesis, occuring in precursor lesions and CRC. Thus we
conclude that DNA hypermethylation is an early and systematic event in colorectal carci-
nogenesis, and it could be potentially reversed by systematic demethylation therapy, but it
would need more in vitro and in vivo experiments to support this theory.
PLOS ONE | DOI:10.1371/journal.pone.0133836 August 20, 2015 1 / 19
OPEN ACCESS
Citation: Patai ÁV, Valcz G, Hollósi P, Kalmár A,
Péterfia B, Patai Á, et al. (2015) Comprehensive DNA
Methylation Analysis Reveals a Common Ten-Gene
Methylation Signature in Colorectal Adenomas and
Carcinomas. PLoS ONE 10(8): e0133836.
doi:10.1371/journal.pone.0133836
Editor: Ken Mills, Queen's University Belfast,
UNITED KINGDOM
Received: February 12, 2015
Accepted: July 2, 2015
Published: August 20, 2015
Copyright: © 2015 Patai et al. This is an open
access article distributed under the terms of the
Creative Commons Attribution License, which permits
unrestricted use, distribution, and reproduction in any
medium, provided the original author and source are
credited.
Data Availability Statement: The authors confirm
that all data underlying the findings are fully available
without restriction. All .cel files are available at GEO
(Gene Expression Omnibus, http://www.ncbi.nlm.nih.
gov/geo/) under access numbers: GSE4183,
GSE10714, GSE15960, GSE29060 and GSE37364.
Funding: This study was supported by the National
Office for Research and Technology, Hungary, (Grant
number: TECH_08-A1/2-2008-0114) and by the
Hungarian Scientific Research Fund (OTKA, Grant
number: K 111743, www.magzrt.hu and www.otka.
hu). The funders had no role in study design, data
Background
Colorectal cancer (CRC) is a clinically and molecularly heterogenous disease [1]. With over 1.2
million new cases annually, it is one of the most frequently occurring malignant diseases world-
wide [2]. Despite considerable advances in the management of CRC, over 600,000 CRC-related
deaths occur annually [2], reflecting a clear need for a better understanding of the disease.
The majority of CRCs arise via the adenoma-carcinoma sequence (ACS), which is thought
to be driven by sequential accumulation of genetic mutations [3]. Recent whole genome
sequencing studies confirmed the early findings that mutations in the APC, KRAS, and P53
genes are frequent events in CRC development (81%, 41%, and 59%, respectively) [4]. Merely
focusing on DNAmutations, however, do not fully depict the molecular complexity of the dis-
ease and consideration of epigenetic changes in CRC pathogenesis has become an intense area
of focus.
Based on accumulating data, epigenetic changes and particularly alterations in the promoter
DNAmethylation are thought to be essential events in the pathogenesis of CRC [5]. It is
known that chronic inflammation induces aberrant hypermethylation in a multitude of genes
in different organs including the colon [6,7]. Surely, thousands of gene promoters, including
many tumor suppressor genes may be hypermethylated in CRC, exceeding the number of
genetic alterations [8]. The origin of such changes in DNAmethylation remains an area of
research. However, studies suggest 4 different molecular pathways that could lead to CRC
[4,9].
A particular CRC subtype that is termed CpG island methlyator phenotype (CIMP) was
first described in 1999 [10]. These CRCs arise from morphologically and molecularly distinct
precursors, called serrated lesions and are predominantly located in the proximal colon [11].
They are characterized by BRAF V600E mutation and the hypermethylation of several genes
[7]. In contrast with CRCs arising via the ACS, a subset of these cancers exhibit microsatellite
instability (MSI) due to hypermethylation and subsequent underexpression of mismatch repair
(MMR) genes (e.g.MLH1,MSH2,MSH6, PMS2), and this type of CRC confers a good progno-
sis. The frequency of sporadic MSI CRCs varies between geographical regions, but it represents
a minority (10–15%) of CRCs, as most CRCs are microsatellite stable (MSS).
The analysis of DNA methylation was initially focused on the global levels of methylated
cytosine. Digestion by methylation-sensitive restriction enzyme, bisulfite conversion and sub-
sequent methylation sequencing and methylation-specific PCR all enable analysis of single, tar-
geted genes [12]. Array technologies are suitable for parallel analysis of multiple gene
promoters [13]. Most recently, bisulfite sequencing of the whole genome has been introduced,
yet deeper insight to CRC-related methylation changes is still limited by the bioinformatic
tools for remapping bisulfite converted, partially methylated sequences [12]. On the other
hand, methods that are based on restricive enzymatic digestion can successfully overcome
these obstacles [13].
In this study, our primary aim was to assess the changes in the DNAmethylation profile
and also to examine KRAS and BRAFmutations in the progression of normal epithelium to
colorectal cancer. To determine whether DNA methylation field effect was present, we ana-
lyzed the normal gut epithelium, CRC precursor lesions and distinct CRCs, as well as the tissue
adjacent to CRCs. In addition, we characterized the status of DNA methylation in our gene
panel for ulcerative colitis (UC) patients, a model to ascertain the impact of chronic inflamma-
tion in the development of CRC. mRNA and protein expression levels were also characterized
to validate the potential tumor suppressor role of selected hypermethylated genes.
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Materials and Methods
Patient groups and ethics statements
Fresh fozen biopsy samples were collected by routine endoscopy and classified based on the his-
tology; tubular adenoma with low-grade dysplasia (LGD, n = 17), adenoma with high-grade dys-
plasia (HGD, n = 6), CRC (n = 17), metastatic CRC (MCRC, n = 7), active UC (UCa, n = 4),
inactive and long-standing UC (UCi, n = 4). As control, patients with normal histology were
used. The normal biopsy samples were collected from adults (older than 18 years, N, n = 5) and
young patients (younger than 18 years, Y, n = 5). For those patients who had normal histology,
the indication for colonoscopy was screening for CRC in adults, and abdominal pain in children.
Field effect was studied by taking samples from at least 10 cm (cancer normal, CN) and 1 cm
away (field, F) from the macroscopically visible margin of the tumor. CRC patients were staged
by the TNM system defined by the Union for International Cancer Control (UICC). Samples
were taken distally from the splenic flexure, collected into RNAlater (Ambion, Life Technologies,
Carlsbad, California, USA), and stored at −80°C until use. Biopsies from the same site were
immediately fixed in buffered formalin for the histological evaluation.
This study was conducted according to the Helsinki declaration and it was approved by the
local ethics committee and government authorities (Regional and Institutional Committee of
Science and Research Ethics (TUKEB) Nr.: 69/2008 and 202/2009, Semmelweis University,
Budapest, Hungary). Written informed consent was obtained in advance from all adult partici-
pants and from the next of kin, caretakers, or guardians on the behalf of the minors/children
approved by the ethics committees.
DNA isolation and methylation-sensitive restriction enzyme methylation
array analysis
For DNA extraction, biopsy samples were homogenized in 2% sodium dodecyl sulphate, and
digested with proteinase K (4 mg/mL) for 16 hours at 56°C. DNA was extracted using High Pure
PCR Template Preparation Kit (Roche, Penzberg, Germany) as instructed by the manufacturer.
DNA was eluted in 2x100 μl RNase- and DNase-free water and stored at -20°C. DNAmethyla-
tion profiles were examined using the EpiTect Methyl qPCR Array System (Qiagen, Hilden, Ger-
many). This method is based on the detection of the remaining DNA input after digestion by
restriction enzyme, coupled with quantitative PCR. Treatment with a methylation-sensitive and
a methylation-dependent restriction enzyme selectively digests unmethylated or methylated
DNA, respectively, and treatment with both enzymes serves as a control for total DNA in the
assay [14]. The relative fractions (%) of hypermethylated, intermediately methylated and
unmethylated DNA are subsequently determined by comparing the amount of methylation in
each digest with a mock digest. 96 genes were evaluated (S1 Table). The threshold for hyper-
methylation was set at 15%. Our aim was to present DNAmethylation as a qualitative data
(hypermethylated yes or no). With a threshold of 15% for hypermethylation, we could signifi-
cantly differentiate between normal and tumorous tissue (S1 Fig). Reactions were performed
according to the manufacturer’s protocol. Briefly, isolated DNA was incubated with either DNA
methylation-dependent or sensitive methylases for 16 h at 37°C, then incubated at 65°C to halt
methylase activity. Each 120 μL reaction contained 500 ng of genomic DNA. Following enzy-
matic digestion, samples were analyzed by fluorescence-based qPCR using LightCycler 480
(Roche). PCR conditions were as follows: 95°C for 10 min, 40 cycles of 97°C for 15 sec, 72°C for
1 min with realtime data acquisition. To ensure amplification of the desired products, high reso-
lution melting (HRM) analysis was performed following the PCR reaction. The melting curve
range was 65°–95°C, holding for 1 s at increments of 0.04°C for product detection.
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After thermocycling was completed, CT values were exported and 2
-ΔΔCT analysis was per-
formed. Due to the inversely proportional relationship between threshold cycle and the amount
of input DNA, and due to the doubling of PCR product with every cycle in the exponential
phase of the reaction, the initial DNA amount in each digest before PCR was expressed as:
CMo ¼ 2CtðMoÞ; CMs ¼ 2CtðMsÞ; CMd ¼ 2CtðMdÞ; CMsd ¼ 2CtðMsdÞ
The fraction of DNA in each digest was calculated by normalizing the DNA amount to the
amount of digestible DNA. The amount of digestible DNA is equal to the total amount of
DNA (determined from the mock digest) minus the amount of DNA resistant to DNA diges-
tion (determined from the double digest).
Hypermethylated (HM) DNA Fraction:
FHM ¼
CMs
CMo  CMsd
¼ 2
CtðMsÞ
2CtðMoÞ  2CtðMsdÞ
Unmethylated (UM) DNA Fraction:
FUM ¼
CMd
CMo  CMsd
¼ 2
CtðMdÞ
2CtðMoÞ  2CtðMsdÞ
The equations were formatted in MathType 6.9 (Design Science, Long Beach, CA, USA).
Bisulfite PCR analysis and validation studies
Genomic DNA samples were bisulfite converted using EZ DNAMethylation-Direct Kit (Zymo
Research, Irvine, CA, USA). To ensure efficient conversion, the maximum amount of input
DNA did not exceed 500 ng per reaction, as suggested by the manufacturer. Eluted bisulfite
modified DNA was quantified with Qubit 2.0 Fluorometer (Invitrogen, Life Technologies,
Grand Island, NY, USA).
PCR and sequencing primers specific to relevant CpG island regions of previously selected
genes indicated in CRC progression were designed using PyroMark Assay Design 2.0 (Qiagen)
and BiSearch (Institute of Enzymology, Hungarian Academy of Sciences, Budapest, Hungary)
software. CpG islands were identified using the UCSC Genome Browser database and CpG Plot
(EMBOSS) software. PCR amplification and HRMwere carried out sequentially on a LightCycler
480 instrument. Reaction volume was 15 μl and contained 1x AmpliTaq Gold PCRMaster Mix
(Applied Biosystems, Life Technologies), 0.25 μl ResoLight Dye (Roche), 1.5 mMMgCl2, 0.13 μM
of each primer (Invitrogen), and 3 ng of bisulfite converted template. The amplification consisted
of a denaturing step for 10 min at 95°C, followed by 9 cycles of touchdown from 65°C to 55°C
with a ramp rate of 2.2°C, then 40 cycles of 95°C for 30 s, 55°C for 30 s, and 30 s 72°C. All
reactions were performed in duplicate. Primer sequences were: MAL-f GGAAAAA
TTGGGTTTTTAATTGGGGTTAG, MAL-r TTCAACTCCCTCTCATCTCCAAATCTC,
(target area: chr2:95026139–95026340 on the hg38 genome, corresponding to 456–657 bp
downstream from the transcriptional start), SFRP1-f ATTTAGGAGGTTGTAGGGTTGGA,
SFRP1-r TTCCCCTTCTTTTTCTCCCCTTATC (target area: chr8:41309468–41309682 on
the hg38 genome, corresponding to 2 to -213 bp from the transcriptional start, SFRP2-f
GTTGTTAGAGAGGGGGATGTAAAGG, SFRP2-r ATACCACCCCAACACCAAAAAA
TTCCTAT (target area: chr4:153788387–153788549 on the hg38 genome, corresponding to
524–686 bp downstream from the transcriptional start. HRM analysis used a melting profile
from 50 to 95°C with a ramp rate of 0.03°C/s and 20 acquisitions per °C. Unmethylated (0%)
and methylated (100%) DNA standards were used from EpiTect Control DNA Kit (Qiagen).
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RNA extraction and whole genomic mRNA expression microarray
analysis
Total RNA was extracted by using RNeasy Mini Kit according to the manufacturer’s instruc-
tions (Qiagen, Hilden, Germany). Whole genomic mRNA expression microarray analysis was
performed previously by our group [15]. Briefly, biotinylated cRNA probes were synthesized
fragmented using the One-Cycle Target Labeling and Control Kit (http://www.affymetrix.com/
support/downloads/manuals/expression_s2_manual.pdf), according to the Affymetrix descrip-
tion. Two-cycle T7-based linear amplification was performed according to instructions of the
manufacturer (Affymetrix Inc., Santa Clara, CA, USA). A volume of 10 mg of each fragmented
cRNA sample was hybridized into HGU133 Plus2.0 array (Affymetrix) at 45°C for 16 h. Slides
were washed and stained using Fluidics Station 450 and an antibody amplification staining
method according to the manufacturer’s instructions. Fluorescent signals were detected by a
GeneChip Scanner 3000 (Affymetrix). Data sets are available at the Gene Expression Omnibus
database (GEO, http://www.ncbi.nlm.nih.gov/geo/) under access numbers: GSE4183,
GSE10714, GSE15960 and GSE37364 [15–18].
In vitro and in silico data
5-aza-2’-deoxycytidine treatment was performed as described previously [15,18.] HT29 colon
adenocarcinoma cells (ATCC Number: HTB-38) were cultured at 37°C with 5% CO2 in RPMI-
1640 medium (Sigma-Aldrich, St Louis, MO, USA) containing 10% FCS. In 25 cm2 cell culture
flask, 1 500 000 cells/flask were cultured for 24 hours, then for demethylation the cells were
treated with 10 μM 5-aza-2’-deoxycitidine (Sigma-Aldrich) for 72 hours in FCS-free medium.
The treatment was carried out in 3 parallel experiments. In the control cultures PCR-grade
water and acetate, the solvent of 5-aza-2’-deoxycitidine was added in 1:1 ratio. Whole genomic
mRNA expression microarray analysis was performed as described above [15]. Data set is
available at the Gene Expression Omnibus database (GEO, http://www.ncbi.nlm.nih.gov/geo/)
under access number: GSE29060 [18]. Concerning molecular phenotype, HT29 cell line is
MSS, KRAS wild type, BRAF V600E mutant [19]. For additional in silico analysis, microarray
dataset using MSI-high, KRAS mutant, BRAF wild type CRC cell line HCT116, and re-expres-
sion array analysis by 5-aza-2’-deoxycytidine/Trichostatin A performed by an other research
group was downloaded from the Gene Expression Omnibus (GEO) database (GSE14526) [20].
Immunohistochemistry analysis of MMR proteins and SFRP1
Tissue microarrays (TMAs) were constructed with 2 mm cores from formalin-fixed and paraf-
fin-embedded tissues. TMA sections were fixed on Superfrost Plus slides (VWRI, Leicester-
shire, UK) and incubated overnight at 37°C. Immunohistochemistry analysis was performed as
previously described [21]. Following dewaxing and rehydration, endogenous peroxidase activ-
ity was blocked with 2.5% hydrogen peroxide in methanol for 30 minutes. The antigen retrieval
was carried out in an electric pressure cooker for 40 minutes in TRIS-EDTA buffer (pH 9).
After blocking in 1% bovine serum albumin, slides were incubated overnight at 58°C with
monoclonal antibodies for MLH1 (1:80), MSH2 (1:80), MSH6 (1:80), PMS2 (1:150, all from
Santa Cruz, California, USA), and SFRP1 (1:150, Abcam, Cambridge, UK). The antibody
detection was carried out using the HISTOLS-MR-T kit (Hisztopatológia Kft., Pécs, Hungary)
and visualized with 3,3'-diaminobenzidine Liquid and Substrate Chromogen System (Dako
Cymation, Glostrup, Denmark). Slides were counterstained with haematoxylin, dehydrated
with xylol, and mounted. After digital archiving (Pannoramic Flash 250 instrument, 3DHIS-
TECH Ltd., Budapest, Hungary), stainings were evaluated with a Pannoramic Viewer digital
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microscope (software version 1.15; 3DHISTECH). A tumor was scored MSS if all four MMR
proteins showed expression. SFRP1 protein expression was scored as follows: 0 (no immunor-
eaction), 1 (weak), 2 (moderate), and 3 (strong, diffuse cytoplasmic staining).
BRAF and KRASmutational analysis
All samples were analyzed for BRAF V600E and KRAS codon 12 and 13 mutations. BRAF
mutation analysis was performed as previously described [22]. Briefly, 20 ng of genomic DNA
and 12.5 μL of HotStarTaq Master Mix (Qiagen) was put in a final reaction volume of 25 μL.
Thermal cycling conditions were 95°C for 12 min, followed by 40 cycles of 95°C for 10 s, 55°C
for 20 s, and 72°C for 20 s. Primers used were this analysis were:
BRAF_fw_BIO: TCCAGACAACTGTTCAAACTGAT,
BRAF_rev: TGAAGACCTCACAGTAAAAATAGG,
BRAF_seq: TGATTTTGGTCTAGCTACA.
Targeted analysis of BRAF was performed by using pyrosequencing technology on a Pyro-
Mark Q24 instrument (Qiagen) and PyroMark Q24 software (Qiagen), following the manufac-
turer’s protocols. Activating KRASmutations in codons 12 and 13 were tested by mutagenic
PCR-RFLP analysis described elsewhere [23] with several modifications. Briefly, formalin-
fixed, paraffin-embedded tissue sections were deparaffinized in xylene and ethanol. After dry-
ing, proteinase K digestion was performed overnight at 50°C, followed by heat inactivation at
94°C for 10 min. 10–20 ng unpurified DNA was amplified per PCR reaction. In addition, the
final volume of 20 μl PCR mixture contained 1x ImmoMix Red (Bioline, London, UK) adjusted
to 3.5 mM final MgCl2 concentration and 0.5 μM of each primer. Amplification was carried
out in a Veriti 96-Well Fast Thermal Cycler (Applied Biosystems, Life Technologies) and the
protocol was 10 min at 95°C, 10 cycles of 95°C for 40 s, 58°C for 40 s, and 72°C for 40 s, then
30 cycles of 86.5°C for 40 s, 58°C for 40 s, and 72°C for 40 s, and finally 72°C for 10 min. The
primers used were as follows:
Mc12-f ACTGAATATAAACTTGTGGTAGTTGGACCT,
Mc12-r CTGTATCAAAGAATGGTCCTGGACCAGTA,
Mc13-f ACTGAATATAAACTTGTGGTAGTTGGCCCTGGT,
Mc13-r AGAAGCCTTTATGGCTATCAAAGAATGGTCCTGCACCAGTA.
PCR products for codons 12 and 13 were digested with restriction endonucleases BstNI or
BglI (New England Biolabs, Ipswich, MA, USA), respectively, and analyzed on Experion Auto-
mated Electrophoresis Station (Bio-Rad, Hercules, CA, USA). For codon 12, cleavage of the
162 bp long PCR product yielded a 113 or 142 bp fragment, while for codon 13, the 174 bp
product was truncated to a 165 or 125 bp fragment, depending on whether the allele was wild
type or mutant, respectively.
Statistical analyses
Data are expressed as mean±standard deviation (SD) if not stated otherwise. Student’s t-tests,
ANOVA were used for comparison. A p-value of<0.05 was considered to be significant. All
statistical analyses were performed by using the R-environment [24].
Results
Methylation profile of precursor lesions compared to CRC reveals more
hypermethylated genes in precancerous lesions
Comparison of methylation profiles between CRCs, precancerous lesions (Table 1), inflamed
and normal colorectal mucosa (Table 2) revealed that CRC and precancerous lesions have a
characteristic methylation signature (Table 1). We identified a set of 10 genes that were
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hypermethylated in at least 85% of tumor samples (Table 1). These genes were not hyper-
methylated in MCRC, indicating that metastatic CRCs have a different epigenetic signature.
The highest mean methylation in the tumor samples were observed in HGD, followed by
LGD, then by CRC, being the lowest in MCRC (Table 3).
DNA methylation profiling revealed an increasing number of methylated genes along ACS.
In addition to the 9 hypermethylated genes found in the majority (>95%) of samples, including
normal and UC tissue (Table 3), additional 34, 46 and 32 hypermethylated genes were observed
in more than half of LGD, HGD and CRC samples, respectively. In MCRC only 2 additional
hypermethylated genes were observed (Table 3). A set of 12 genes were exclusively hyper-
methylated in HGD (Table 3). The frequency of hypermethylated DNA copies was also signifi-
cantly higher in the premalignant alterations than in cancer.
Methylation levels and penetrance of genes in precancerous and CRC
lesions: confirmation from parallel alterations
The level of DNA methylation was higher in precancerous lesions (LGD and HGD), compared
to CRC (Table 3). This observation was further validated in 7 synchronous LGD-CRC pairs
where methylation levels proved to be greater in LGD than in synchronous CRC (Fig 1, S2
Fig). This observation was also confirmed by bisulfite-HRM analysis in 3 genes and showed
consistent results (S3 Fig). The number of hypermethylated genes was also higher in LGD,
than in synchronous CRC (Fig 1, S2 Fig). The mean DNAmethylation percentage of methyl-
ated genes was significantly higher in LGD than in CRC (S2 Fig). The comparison of DNA
methylation profiles between CRC and NAT revealed that hypermethylation occurred only in
cancer but not in the adjacent field (Table 3A–3D).
Hypermethylated genes have a higher penetrance than mutations
All samples were MSS. 25% of the samples harbored KRASmutations and 10% exhibited BRAF
V600E mutation (Table 4). Although only 2 genes merely does not represent all genetic
Table 1. Methylation status and frequency of top 10 hypermethylated genes in tumor samples. List of the top 10 genes that were hypermethylated in
at least 85% of benign and malignant tumor samples. The highest mean methylation was observed in dysplastic lesions, followed by stage I-III cancer sam-
ples, whereas samples from patients with metastatic cancer had the lowest level of hypermethylation. SD: standard deviation. *Tumors: low-grade dysplasia,
high-grade dysplasia, colorectal cancer stage I-III.
Low-grade dysplasia
(n = 17)
High-grade
dysplasia
(n = 6)
Colorectal
cancer
(n = 17)
Tumors*
(n = 40)
Metastatic colorectal
cancer (n = 7)
Gene
name
Mean
methylation
% ± SD
Methylated
cases (%)
Mean
methylation
% ± SD
Methylated
cases (%)
Mean
methylation
% ± SD
Methylated
cases (%)
Methylated
cases (%)
Mean
methylation
% ± SD
Methylated
cases (%)
SFRP1 60.66±25.27 100 54.93±30.99 100 31.67±16.36 94 97,5 7.56±2.1 0
SST 35.57±23.77 94 49.74±23.41 100 30.98±14.29 94 95 15.53±8.99 57
BNC1 63.95±24.45 100 53.8±17.43 100 31.99±14.53 88 95 20.15±3.63 57
MAL 51.79±30.94 100 41.39±30.32 83 37.14±18.83 88 92,5 10.21±9.15 14
SLIT2 58.58±32.95 100 47.79±29.48 100 26.32±17.86 82 92,5 9.12±3.4 0
SFRP2 48.49±34.63 82 51.63±30.57 100 27.49±14.35 94 90 5.26±4.52 0
SLIT3 38.44±30.9 94 41.46±22.63 100 27.08±21.36 76 87,5 5.78±8.52 14
ALDH1A3 53.95±38.12 88 74.36±18.83 100 37.22±23.74 76 85 6.73±2.64 0
TMEFF2 45.87±31.23 94 53.79±40.26 83 25.27±17.33 76 85 7.5±7.49 14
WIF1 44.27±30 88 49.89±40.45 83 30.32±21.16 82 85 19.1±16.62 29
doi:10.1371/journal.pone.0133836.t001
DNAMethylation Signature in Colorectal Adenomas and Carcinomas
PLOSONE | DOI:10.1371/journal.pone.0133836 August 20, 2015 7 / 19
T
ab
le
2.
M
et
h
yl
at
io
n
st
at
u
s
an
d
fr
eq
u
en
cy
o
ft
h
e
ab
o
ve
to
p
10
h
yp
er
m
et
h
yl
at
ed
g
en
es
in
n
o
rm
al
(y
o
u
n
g
an
d
ad
u
lt
),
n
o
rm
al
ca
n
ce
r
ad
ja
ce
n
t(
10
cm
an
d
1
cm
fr
o
m
th
e
tu
m
o
r
m
ar
g
in
)a
n
d
u
lc
er
at
iv
e
co
lit
is
(i
n
ac
ti
ve
an
d
ac
ti
ve
)s
am
p
le
s.
Y
o
u
n
g
n
o
rm
al
(n
=
5)
A
d
u
lt
n
o
rm
al
(n
=
5)
C
an
ce
r
n
o
rm
al
(1
0
cm
,n
=
5)
F
ie
ld
(1
cm
,n
=
5)
In
ac
ti
ve
u
lc
er
at
iv
e
co
lit
is
(n
=
4)
A
ct
iv
e
u
lc
er
at
iv
e
co
lit
is
(n
=
4)
G
en
e
n
am
e
M
ea
n
m
et
h
yl
at
io
n
%
±
S
D
M
et
h
yl
at
ed
ca
se
s
(%
)
M
ea
n
m
et
h
yl
at
io
n
%
±
S
D
M
et
h
yl
at
ed
ca
se
s
(%
)
M
ea
n
m
et
h
yl
at
io
n
%
±
S
D
M
et
h
yl
at
ed
ca
se
s
(%
)
M
ea
n
m
et
h
yl
at
io
n
%
±
S
D
M
et
h
yl
at
ed
ca
se
s
(%
)
M
ea
n
m
et
h
yl
at
io
n
%
±
S
D
M
et
h
yl
at
ed
ca
se
s
(%
)
M
ea
n
m
et
h
yl
at
io
n
%
±
S
D
M
et
h
yl
at
ed
ca
se
s
(%
)
S
FR
P
1
0.
52
±0
.3
6
0
4.
95
±4
.6
9
0
4.
95
±4
.6
2
0
3.
12
±2
.4
8
0
8.
16
±1
2.
89
25
3.
23
±2
.9
1
0
S
S
T
3.
56
±1
.9
6
0
12
.0
7±
10
.8
4
40
11
.9
9±
5.
51
40
8.
35
±6
.4
2
20
7.
42
±5
.0
9
0
6.
99
±3
.8
8
0
B
N
C
1
2.
02
±1
.0
0
16
.3
7±
17
.4
9
40
11
.6
7±
8.
14
20
8.
71
±5
.1
1
20
12
.8
4±
10
.0
1
25
7.
83
±3
.8
6
0
M
A
L
1.
03
±0
.4
9
0
2.
65
±3
.2
8
0
3.
71
±4
.0
6
0
1.
75
±0
.8
3
0
1.
38
±0
.9
9
0
1.
49
±0
.6
3
0
S
LI
T2
1.
68
±0
.8
9
0
2.
58
±2
.0
0
6.
93
±8
.2
1
20
4.
05
±1
.8
9
0
6.
85
±6
.0
2
25
4.
06
±1
.8
7
0
S
FR
P
2
1.
79
±1
.2
6
0
1.
55
±0
.9
9
0
2.
33
±2
.3
9
0
2.
27
±0
.6
4
0
2.
51
±1
.8
2
0
2.
5±
0.
72
0
S
LI
T3
0.
61
±0
.3
0
2.
49
±2
.8
1
0
1.
36
±1
.0
2
0
1.
25
±0
.4
3
0
4.
93
±5
.5
2
0
1.
39
±0
.5
6
0
A
LD
H
1A
3
0.
75
±0
.4
5
0
4.
12
±3
.3
2
0
3.
77
±1
.9
0
2.
82
±1
.6
9
0
3.
61
±2
.7
4
0
2.
62
±1
.1
9
0
TM
E
FF
2
1.
36
±0
.7
1
0
1.
23
±1
.0
7
0
1.
93
±1
.6
9
0
1.
46
±1
.0
5
0
2.
73
±4
.0
9
0
1.
94
±0
.6
3
0
W
IF
1
2.
63
±1
.6
2
0
8.
14
±6
.7
8
20
13
.7
5±
8.
8
20
8.
59
±5
.3
4
0
16
.2
2±
20
.3
9
20
4.
61
±3
.8
9
0
do
i:1
0.
13
71
/jo
ur
na
l.p
on
e.
01
33
83
6.
t0
02
DNAMethylation Signature in Colorectal Adenomas and Carcinomas
PLOSONE | DOI:10.1371/journal.pone.0133836 August 20, 2015 8 / 19
mutations, but even these frequent mutations occur at a much lower frequency than hyper-
methylated genes, which indicates that hypermethylated genes have a higher penetrance than
mutations, but this should be further evaluated studying more mutations.
Active and passive long-term chronic inflammation resemble the normal
pattern
We analyzed the methylation profile of 4 samples with UCa and 4 samples with UCi. Although
we found difference between methylation levels (e.g. 63% vs 80%, Table 3), both conditions
showed a similar pattern to that of normal samples, no significant changes were observed and
no additional gene was identified as hypermethylated (Fig 2).
Correlation between DNAmethylation, mRNA and protein expression
To analyze the effect of DNA hypermethylation, we examined mRNA and protein expression
levels of SFRP1, a well-described antagonist of the Wnt pathway, frequently aberrantly acti-
vated in CRC. We confirmed the findings of previous studies, that DNA hypermethylation
leads to subsequent underexpression of SFRP1 mRNA (Fig 3A) and lower protein levels
(Fig 3B) in CRC, and also in precursor lesions. In normal samples we found strong, diffuse
cytoplasmic SFRP1 protein expression in the epithelium and in the stroma, as well. In the
stroma, SFRP1 positive cells were localized primarily in close proximity to epithelial cells. In
LGD samples, epithelial SFRP1 protein expression decreased, but in the stroma, it was similar
to that observed in normal samples. In HGD, reduction in epithelial SFRP1 protein expression
was more pronounced than in LGD. In both HGD and CRC, there was no apparent stromal
expression of SFRP1 proximal to the epithelia.
Demethylation treatment increases mRNA expression level of
hypermethylated genes
Whole genomic mRNA expression microarray data was utilized to analyze mRNA expression
of 7 genes previously identified as hypermethylated in CRC. These genes showed decreased
Table 3. Mean DNAmethylation levels for hypermethylated genes sorted by group.
A. Y N CN (10 cm) F (1 cm) LGD HGD CRC MCRC UCi UCa
BAGE 97.39±1.32 76±15.83 79.72±11.97 66.2±21.11 95.43±3.35 93.46±8.09 82.52±18.2 90±11.83 76.65±5.61 78.4±7.83
CCNA1 2.75±1.48 30.76±23.14 24.74±10.49 18.17±10.12 67.1±23.44 61.99±17.72 43.94±9.66 33.46±9.6 23.7±20.65 8.96±4.12
H19 47.91±2.89 46.33±5.82 37.36±7.5 37.17±11.42 33.95±13.46 38.72±15.54 44.16±17.53 42.35±4.89 40.96±12.74 46.39±6.27
MAGEA1 98.18±1.14 73.73±13.92 86.44±9.69 90.08±4.23 79.14±33.83 61.85±44.1 76.63±25–96 90.23±13.21 63.94±15.08 80.93±7.84
MSX1 13.9±3.3 17.26±3.96 20.2±10.87 15.66±5.46 66.64±24.29 57.98±14.36 46.63±17.95 29.4±7.3 34.95±17.57 20.57±4.08
PTGIS 22.95±13.09 43.84±10.57 49.64±4.72 43.29±10.54 79.98±17.71 79.14±17.34 59.71±15.84 56.29±18.53 44.67±20.47 39.43±11.62
RUNX3 34.95±11.62 42.96±12.45 38.94±7.53 37.9±10.99 71.33±21.56 69.82±12.09 58.52±13.82 52.39±9.39 41.59±13.79 56.96±5.15
SPARC 21.42±8.49 42.08±10.87 42.86±6.75 38.97±11.28 65.02±19.86 49.02±33.01 46.86±15.24 45.43±6.01 31.75±17.67 31.34±15.04
UGT1A1 84.15±6.49 51.13±3.28 86.53±8.32 85.75±5.88 91.49±9.46 89.29±10.02 94.9±4.69 81.26±22.83 47.49±3.42 58.42±3.94
B.
BNC1 2.02±1.0 16.37±17.49 11.67±8.14 8.71±5.11 63.95±24.45 53.8±17.43 31.99±14.53 20.15±3.63 12.84±10.01 7.83±3.86
SST 3.56±1.96 12.07±10.84 11.99±5.51 8.35±6.42 35.57±23.77 49.74±23.41 30.98±14.29 15.53±8.99 7.42±5.09 6.99±3.88
C.
ADAMTS1 0.56±0.66 0.37±0.34 0.49±0.75 0.52±0.39 19.38±29.92 43.26±35.45 18.18±19.41 1.23±0.87 0.83±0.57 0.15±0.57
ALDH1A3 0.75±0.45 4.12±3.32 3.77±1.9 2.82±1.69 53.95±38.12 74.36±18.83 37.22±23.74 6.73±2.64 3.61±2.74 2.62±1.19
ALX4 0.72±0.59 0.69±0.57 0.8±0.84 0.72±0.2 33.94±35.79 51.47±41.78 27.76±26.83 1.26±1.04 1.34±0.98 0.94±0.42
CDH13 1.6±0.92 1.23±0.85 3.93±3.82 2.47±0.98 32.79±34.53 33.47±27.99 25.75±25.35 3.7±2.82 2.42±2.64 3.08±1.56
(Continued)
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Table 3. (Continued)
A. Y N CN (10 cm) F (1 cm) LGD HGD CRC MCRC UCi UCa
DKK2 4.21±0.93 8.6±4.47 5.09±3.25 4.13±0.99 39.93±25.97 46.7±17.31 31.54±18.05 7.04±2.99 11.13±13.86 9.11±4.77
DKK3 1.61±1.45 1.95±0.52 2.02±2.76 1.31±0.19 21.04±28.46 32.3±32.37 23.36±19.79 4.76±5.03 2.89±2.56 1.9±1.03
GALR2 2.24±1.02 2.2±1.65 3.71±2.38 2.18±0.51 37.63±33.64 50.16±29.88 25.88±24.27 5.79±4.12 4.6±2.73 4.33±2.42
HLTF 5.06±1.44 5.39±1.79 4.45±1.34 4.78±1.51 19.71±15.27 33.01±27.9 18.36±15.74 8.17±4.72 6.35±7.34 8.91±4.6
hsa-mir-342 0.53±0.5 1.18±1.61 2.82±2.98 2.14±3.09 42.73±22.86 17.71±27.98 21.27±16.69 3.81±3.23 0.39±0.33 0.4±0.27
LRRC3B 1.44±0.93 3.59±3.61 1.96±1.2 1.1±0.66 26.39±12 35.55±24.78 12.68±10.04 4.94±1.81 3.1±2.77 2.14±1.34
MAL 1.03±0.49 2.65±3.28 3.71±4.06 1.75±0.83 51.79±30.94 41.39±30.32 37.14±18.83 10.21±9.15 1.38±0.99 1.49±0.63
NID1 1.26±0.83 1.43±0.64 1.52±1.52 1.13±0.23 26.86±29.06 24.35±29.84 19.33±19.46 2.28±2.12 2.55±1.6 1.78±0,92
OPCML 2.49±1.05 9.96±11.52 13.03±11.34 7.13±3.54 47.01±19.98 38.1±12.77 20.62±15.2 12.54±3.24 8.74±10.68 4.79±1.95
PAX2 1.16±0.5 0.81±0.65 1.19±1.04 1.26±1.02 26.5±34.37 42.74±37.46 19.97±19.1 1.23±1.33 1.49±1.73 0.99±0.53
PCDH10 1.53±0.52 3.44±1.4 3.98±1.89 3.4±1.24 44.79±29.1 57.28±35.04 21.77±18.49 7.43±5.2 7.73±10.11 3.65±1.8
PDLIM4 2.75±0.99 12.22±11.22 7.14±3.09 7.48±4.1 40.94±39.99 77.39±20.48 28.69±21.67 12.48±7.97 13.24±8.87 7.05±3.16
RBP1 1.18±0.52 1.44±0.81 3.08±2.29 1.15±0.45 42.22±39.03 39.55±38 20.34±13.8 3.88±4.7 1.57±1.79 1.9±0.86
RPRM 2.19±0.95 2.97±1.62 4.38±1.87 2.81±0.66 25.62±28.93 26.88±33 21.41±19.23 10.25±6.48 8.4±6.9 4.76±1.26
SFRP1 0.52±0.36 4.95±4.69 4.95±4.62 3.12±2.48 60.66±25.27 54.93±30.99 31.67±16.36 7.56±2.1 8.16±12.89 3.23±2.91
SFRP2 1.79±1.26 1.55±0.99 2.33±2.39 2.27±0.64 48.49±34.63 51.63±30.57 27.49±14.35 5.26±4.52 2.51±1.82 2.5±0.72
SLC16A12 0.85±0.94 0.89±0.63 1.64±1.67 0.92±0.23 25.78±29.43 41.5±39.64 21.53±21.37 2.24±1.3 4.04±4.44 1.76±0.94
SLIT2 1.68±0.89 2.58±2 6.93±8.21 4.05±1.89 58.58±32.95 47.79±29.48 26.32±17.86 9.12±3.4 6.85±6.02 4.06±1.87
SLIT3 0.61±0.3 2.49±2.81 1.36±1.02 1.25±0.43 38.44±30.9 41.46±22.63 27.08±21.36 5.78±8.52 4.93±5.52 1.39±0.56
TAC1 2.2±1.63 6±4.42 4.73±2.38 8.9±8.73 22.51±27.98 30.17±16.38 18.84±19.05 15.36±10.11 15.39±14.47 6.13±2.19
TMEFF2 1.36±0.71 1.23±1.07 1.93±1.69 1.46±1.05 45.87±31.23 53.79±40.26 25.27±17.33 7.5±7.49 2.73±4.09 1.94±0.63
UCHL1 2.83±1.21 2.68±2.3 2.07±2.23 2.43±0.04 29.26±35 57.78±34.35 23.29±17.5 6.27±6.03 2.24±1.62 3.79±1.9
VIM 1.54±0.65 0.65±0.5 0.89±0.99 0.84±0.88 40.03±34.38 46.53±40.81 27.35±22.14 3.32±3.86 2±1.63 1.92±1.27
WIF1 2.63±1.62 8.14±6.78 13.75±8.8 8.59±5.34 44.27±30 49.89±40.45 30.32±21.16 19.1±16.62 16.22±20.39 4.61±3.89
D.
DAB2IP 1.12±0.35 1.35±0.18 0.8±0.4 0.59±0.21 20.01±26.99 27.52±23.65 8.7±7.24 6.33±10.34 2.81±0.49 0.73±0.25
HS3ST2 1.35±0.6 1.36±0.12 1.16±1.02 0.81±0.03 31.13±36.33 29.69±26.42 13.45±12.23 1.88±1.55 3.28±1.01 0.78±0.16
IGFBP3 0.23±0.32 0.22±0.26 0.3±0.29 0.29±0.21 11.03±15.37 22.92±30.86 11.98±18.37 0.5±0.5 1±1.18 0.47±0.2
WT1 0.44±0.25 0.73±0.56 0.97±1.07 0.4±0.34 22.06±31.12 31.78±31.99 12.99±19.58 1.18±1.15 1.78±1.86 0.85±0.84
CALCA 8.37±1.09 8.78±2.71 8.22±4.01 13.57±11.74 8.72±4.24 30.74±27.13 18.92±14.32 12.29±5.2 14.52±9.31 18.07±3.38
MCC 4.74±1.71 2.78±1.19 2.89±1.87 2.12±0.93 11.99±14.96 34.09±28.85 17.38±15.11 6.87±6.61 3.61±2.91 5.87±3.14
BMP3 0.17±0.23 0.12±0.02 0.18±0.26 0.07±0.02 8.65±18.27 31.09±30.12 9.46±13.85 0.21±0.27 0.27±0.07 0.07±0.01
CHFR 0.46±0.09 0.41±0.23 0.3±0.16 0.35±0.08 6.83±11.39 20.56±27.57 5.4±6.1 0.25±0.53 0.42±0.74 0.28±0.18
DACT2 0.67±0.17 0.75±0.39 1.26±1.02 1.17±0.6 4.23±6.02 33.62±31.64 6.41±11.25 1.82±1.69 2.14±1.89 2.3±0.64
EYA2 2.06±0.96 0.55±0.5 1.16±1.46 1±0.27 3.6±5.86 30.98±37.86 10.84±16.92 1.4±1.37 2.24±1.47 2.07±1
NKX2 0.78±0.62 0.88±0.48 0.68±0.72 0.55±0.12 6.82±8.83 34.85±41.31 6.17±10.95 1.26±0.67 1.83±0.56 1.2±0.42
SFRP5 2.51±1.58 2.61±1.93 1.12±1.21 0.95±0.36 15.57±27.23 15.35±10.84 9.24±10.4 2.09±1.36 2.95±0.8 3.3±1.86
SLC5A8 0.85±0.44 3.42±3.73 2.69±1.75 3.58±1.29 12.15±13.15 34.12±42.53 11.46±19.21 4.59±3.11 2.24±0.81 3.52±1.01
TFAP2C 2.43±1.06 0.99±1.19 1.1±1.37 0.63±0.42 12.47±19.71 26.11±38.62 7.27±15.74 1.78±2.38 1.9±0.9 3.16±1.47
WNT5A 0.37±0.38 0.05±0.07 0.03±0.03 0±0 0.75±2.19 21.44±31.86 0.8±2.17 0.18±0.35 0.17±0.32 0.05±0.1
WRN 1.75±0.79 1.51±0.16 3.55±1.01 3.68±1.03 2.82±1.89 19.17±16.27 5.7±7.5 2.41±1.22 3.73±1.14 1.24±0.59
A. Genes commonly methylated in >95% of all samples.
B. Genes methylated in all tumorous samples (including MCRC).
C. Genes methylated only in LGD, HGD and stage I-III CRC.
D. Genes individually methylated in certain groups.
Y: young normal, N: adult normal, CN: macroscopically normal tissue taken from at least 10 cm away from the tumor margin, F: macroscopically normal
tissue taken from 1 cm away from the tumor margin, LGD: low-grade dysplasia, HGD: high-grade dysplasia, CRC: colorectal cancer, MCRC: metastatic
CRC, UCi: inactive ulcerative colitis, UCa: active ulcerative colitis. Bold: genes hypermethylated in more than half of the samples in the representative
group.
doi:10.1371/journal.pone.0133836.t003
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mRNA expression in CRC compared to normal tissue in the majority of the examined samples
(Fig 4A).
To examine whether downregulation of these gene can be reversed by demethylation, 5-aza-
2’-deoxycytidine treatment was applied to HT-29 cells. The treatment was carried out in 3 par-
allel experiments and partly restored mRNA expression of these genes, indicating that DNA
hypermethylation seems to play a role in the regulation of these genes (Fig 4B). Similar ten-
dency was oberved in another experiment, where 5-aza-2’-deoxycytidine treatment was applied
to HCT116 cell line (S4 Fig).
Discussion
In this study we compared DNAmethylation profiles of normal colorectal tissue, colorectal
precancerous lesions, and CRC tissue. We also examined the effect of chronic inflammation
and field effect. We focused on distal colorectal carcinogenesis, which is known to emerge via
the traditional adenoma-cancer pathway and driven by the sequentional accumulation of
genetic mutations. In a recent genome-wide array-based study 2 classes (high-frequency meth-
ylation and low-frequency methylation) of adenomas were identified based on their DNA
methylation patterns [25]. We only included MSS samples to ensure molecular homogeneity in
our study. To date, there has only been one study dedicated to the characterization of DNA
methylation in CIMP-negative tumors [26]. This study however focused only on CRC, exam-
ined few genes, and did not characterize precursor lesions. Furthermore, we used a wider set of
Fig 1. DNAmethylation heatmap for synchronous LGD and CRC samples from the same patient. The
number of hypermethylated genes and methylation levels were higher in LGD than in synchronous CRC.
doi:10.1371/journal.pone.0133836.g001
Table 4. Frequency and percentage of KRAS and BRAFmutations in normal (N), low-grade dysplasia
(LGD), high-grade dysplasia (HGD) and colorectal cancer (CRC) samples.
n KRAS c12 % KRAS c13 % BRAF V600E %
N 20 0 0 0 0 0 0
LGD 17 4 24% 0 0 3 18%
HGD 6 1 17% 0 0 1 17%
CRC 17 4 24% 1 6% 0 0
Total 40 9 22.5% 1 2.5% 4 10%
doi:10.1371/journal.pone.0133836.t004
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96 candidate genes, for which hypermethylation has frequently been described in gastrointesti-
nal cancers.
Our results indicate that there is a characteristic methylation pattern for MSS CRCs, but
also for their precursor lesions. We identified a set of 10 genes that are frequently hypermethy-
lated in benign and malignant colorectal tumors. More interestingly precursor lesions had
more hypermethylated genes and a higher grade of methylation than CRC, when synchronous
LGD and CRC pairs were compared. One possible explanation for this phenomenon would be
the higher epithelium-stroma ratio in hyperprolipherative precursor lesions, than in CRC.
According to an other theory, since cancerous cells develop from dysplastic cells, CRC samples
could contain significant amount of dysplastic (but not yet cancerous) cells. In that case the
hypermethylation of 10 genes can be specific for dysplastic samples and their presence in CRC
samples is a result of “contamination” with dysplastic cells. Further characterization of the 10
genes did not reveal common features as they were located on 7 different chromosomes and
have distinct biological functions. The examined genes were seperately evaluated and charac-
terized for CRC in previous studies [27–43]. Interestingly, in most studies these markers
showed a similar or somewhat weaker performance, as compared to our results (Table 5). We
have to note that our study used fresh frozen samples and a real time PCR restriction-based
method. These differences in methodology may contribute to the better sensitivity as compared
to those observed in previous studies. Furthermore, we confirmed that metastatic CRCs have a
different DNAmethylation fingerprint [44], as most of the genes hypermethylated in
Fig 2. Methylation levels in various groups in the top 10 hypermethylated genes.No significant methylation changes were observed among different
groups. Y: young normal, N: adult normal, CN: macroscopically normal tissue taken from at least 10 cm away from the tumor margin, F: macroscopically
normal tissue taken from 1 cm away from the tumor margin, LGD: low-grade dysplasia, HGD: high-grade dysplasia, CRC: colorectal cancer, MCRC:
metastatic CRC, UC: inactive ulcerative colitis, UCa: active ulcerative colitis
doi:10.1371/journal.pone.0133836.g002
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Fig 3. A. Gene expression of SFRP1 during ACSmeasured by mRNA expression microarray analysis. As indicated, transcript levels decreased
across in LGD, HGD and CRC samples in 3 out of 4 SFRP1 transcripts. B. Protein expression of SFRP1 protein measured by
immunohistochemistry. SFRP1 protein expression gradually decreased during ACS. The epithelial SFRP1 expression showed a continuous decrease
during ACS. Epithelial SFRP1 expression was decreased in LGD compared to normal epithelium, but stromal SFRP1 protein expression was retained. In
HGD and CRC samples, both epithelial and stromal SFRP1 protein expression was significantly reduced. Red staining: SFRP1, blue staining: Hoechst
nuclear staining. N: normal sample, LGD: low-grade dysplasia, HGD: high-grade dysplasia, CRC: colorectal cancer
doi:10.1371/journal.pone.0133836.g003
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precancerous and cancerous lesions were not methylated in MCRC. We think that hyper-
methylated genes characteristic for MCRC might have not been included in our array, however
this should be further evaluated in subsequent studies.
We showed that 7 genes had decreased mRNA expression in tumorous samples, and this
decreased mRNA expression could be partly restored by demethylation treatment. This indi-
cates that DNA hypermethylation might play a role in the regulation of these genes and
demethlyation could potentially reverse these changes indicating a yet undiscovered systematic
underlying mechanism, however this should be further studied to draw firm conclusions.
Among these, SFRP1 was analyzed also at the protein level and showed decreased protein
expression compared to healthy samples. Concerning SFRP1 our data are consistent with pub-
lished studies [27,45], which provide evidence for hypermethylation and consequential under-
expression of SFRP1, promoting tumor formation. SFRPs are well-known inhibitors of the
Wnt pathway. Abnormal activation of the Wnt pathway (e.g. via APC mutation, beta-catenin
translocation) is a frequent and early event in colorectal carcinogenesis [4]. The hypermethyla-
tion of this gene may also be an early event that can be harnessed in future studies addressing
the potential of hypermethylated SFRP1 in early detection of CRC. As we along with others
have shown, DNA methylation is a promising blood-based biomarker for early detection of
CRC and could potentially substitute routinely used, more invasive screening methods [46–
48].
When the frequency of mutations and hypermethylated genes in tumorous samples was
compared, methylated genes showed a significantly higher penetrance than mutations. We
identified 10 genes that were hypermethylated in more than 85% of the examined samples,
whereas mutations were less frequent, further underscoring the importance of DNA methyla-
tion in colorectal carcinogenesis.
One aspect of this study was to determine if we could correlate changes in DNAmethylation
with initial steps in the carcinogenesis pathway, first in terms of field effect, and secondly in
chronic inflammation, a condition considered as a CRC risk factor. With respect to field effect,
Fig 4. mRNA expression of 7 genes in normal and colorectal cancer biopsy (A) and in HT29 cells after 5-aza-2’-deoxycytidine treatment (B). A.
Compared to normal, CRC showed decreased mRNA expression. B. In HT29 cells, demethylation treatment partly restored mRNA expression. N: normal,
CRC: colorectal cancer, AZA: 5-aza-2’-deoxycytidine treatment.
doi:10.1371/journal.pone.0133836.g004
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Shen et al observed the DNA repair gene O6-methylguanine-DNA methyltransferase (MGMT)
to be hypermethylated and silenced in colorectal tumors, but also in the surrounding mucosa
[49], providing proof of principle for the field effect of methylation in CRC. This phenomenon
was later described for several other genes [50]. Our samples were taken 1 cm and 10 cm away
from the margin of the tumor, from the macroscopically normal colorectal mucosa. These
showed a similar pattern to healthy controls, suggesting the lack of a field effect for genes in
this study. We have to note, that all of our samples were MSS, whereas methylation ofMGMT
was associated with the development of low level microsatellite instability (MSI-L) CRC [51].
With respect to chronic inflammation, this condition has been proposed to lead to DNA
hypermethylation in non-cancerous tissues, that can be detected and used as a risk factor for
cancer [8]. However, our study did not reveal any DNAmethylation markers that were predic-
tive of CRC in ulcerative colitis patients as a model for chronic inflammation of the gut.
In conclusion, our study has confirmed that hypermethylation of certain genes is character-
istic for MSS cancer. We have shown for the first time that precursor lesions, especially those
with low-grade dysplasia, exhibit more hypermethylated genes. These genes are more densely
hypermethylated, than their matched cancer pairs. We identified potential hypermethylated
genes, including SFRP1 andMAL that might be useful in the early detection of CRC and help
to prevent this otherwise deadly disease.
Supporting Information
S1 Fig. Treshold for hypermethylation at different genes. Threshold for hypermethylation
was set at 15% after comparing normal and cancerous samples in several genes.
(PDF)
Table 5. Comparison of performance of top genes in our study and previous single gene studies.
N (%) LGD (%) HGD (%) CRC (%) TU (%, n = 40) Reference N % AD % CRC % Method
SFRP1 0 100 100 94 97,5 Caldwell 2004 11/36 30% n.a. 40/49 82% MSP, COBRA
Qi 2006 0/20 0% 29/33 88% 67/72 88% MSP
SST 18 94 100 94 95 Mori 2006 n.a. n.a. 30/34 88% MSP
BNC1 18 100 100 88 95 Shames 2006 n.a. 10/24 42% 22/24 92% MSP
MAL 0 100 83 88 92,5 Lind 2008 1/23 4% 45/63 71% 49/61 80% MSP
SLIT2 7 100 100 82 92,5 Dallol 2003 n.a. n.a. 23/32 72% BS
SFRP2 0 82 100 94 90 Qi 2006 0/20 0% 27/33 82% 60/72 83% MSP
SLIT3 0 94 100 76 87,5 Dickinson 2004 n.a. n.a. 12/32 38% COBRA
ALDH1A3 0 88 100 76 85 Shames 2006 n.a. 7/17 29% 11/24 46% MSP
TMEFF2 0 94 83 76 85 Ebert 2005 1/21 5% n.a. 36/47 71% Methylight
WIF1 11 88 83 82 85 Taniguchi 2005 n.a. 32/44 73% 41/50 82% MSP
PCDH10 4 88 83 76 82,5 Zhong 2013 n.a. n.a. 68/80 85% MSP
PDLIM4 (RIL) 11 82 100 76 82,5 Boumber 2007 1/22 5% 11/13 85% 30/43 70% COBRA
VIM 0 82 83 76 80 Kann 2006 0/11 0% 25/50 50% 72/94 77% MSP
GALR2 0 76 100 71 77,5 Chung 2008 0/20 0% n.a. 17/20 85% COBRA, PS
DKK2 7 88 100 59 77,5 Sato 2007 n.a. n.a. 45/58 78% MSP
OPCML 14 94 83 59 77,5 Cui 2008 n.a. n.a. 17/18 94% MSP
UCHL1 0 65 83 82 75 Okochi-Takada 2006 1/17 6% n.a. 8/17 47% MSP
Mizukami 2008 n.a. n.a. 36/49 73% MSP
COBRA: Combined bisulfite restriction analysis, MSP: methylation-specific polymerase chain reaction, PS: pyrosequencing, N: normal, LGD: low-grade
dysplasia, HGD: high-grade dysplasia, CRC: colorectal cancer, TU: precancerous and cancerous tissue (except metastatic colorectal cancer), AD:
adenoma (level of dysplasia not specified).
doi:10.1371/journal.pone.0133836.t005
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S2 Fig. Mean DNAmethylation percentage of methylated genes in synchronous LGD and
CRC. The mean DNA methylation percentage of methylated genes was significantly higher in
LGD than in CRC. LGD: low-grade dysplasia, CRC: colorectal cancer
(TIF)
S3 Fig. High resolution melting (HRM) profile derivative plots (-d/dT against T). The
inflection point on each standard melting curve is visualized here as a melting peak. Panels on
the left show the degree of DNA methylation in normal (N) versus colorectal carcinoma (CRC)
and panels on the right show that in low-grade dysplasia (LGD) versus CRC tissues. Sample
pairs were obtained from the same patient. The melting peaks of methylated DNA standards
(0% and 100%) and no template control (NTC) are also indicated for each gene studied.
(TIF)
S4 Fig. Effect of demethylation (5-aza-2’-deoxycytidine) treatment on HCT116 cell line
from Yagi et al [20].mRNA expression of some genes can be partly reversed by 5-aza-2’-deox-
ycytidine and trichostatin-A treatment on HCT116 cell line. HCT116 aza0: untreated,
HCT116 aza3: 3 μM 5-AZA treatment for 72 hours, HCT116 aza3_tsa300: additional trichosta-
tin-A (HDAC inhibitor) treatment. White squares indicate that gene expression was
unchanged in that experiment.
(PDF)
S1 Table. The list of examined genes on Methyl Profiler microarray.
(DOCX)
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